Not recruiting
Asthma
Not recruitingRegistered drug
Study on Tezepelumab for Patients with Severe Asthma
Registered drug
- Disease:Asthma
- Substances:Tezepelumab
Countries:
France
France- Participants:18–64 years · 65+ years
- Substances:Tezepelumab
Find therapies in clinical trials near you – page 18
- recruiting
- 3 962
- countries
- 28
- conditions
- 2 101
3 962 trials recruiting28 European countries2 101 conditions coveredUpdated today
296 trials match your criteria
Not recruiting
Juvenile psoriatic arthritis
Not recruitingRegistered drugNo placebo
Study on Ustekinumab and Guselkumab for Children with Active Juvenile Psoriatic Arthritis
Registered drugNo placebo
- Disease:Juvenile psoriatic arthritis
- Substances:GuselkumabUstekinumab
Countries:France
France- Participants:0–17 years
- Substances:Guselkumab
Not recruiting
Adrenoleukodystrophy
Not recruitingInvestigationalNo placebo
Long-term Safety and Efficacy Study of Elivaldogene Autotemcel for Patients with Cerebral Adrenoleukodystrophy
InvestigationalNo placebo
- Disease:Adrenoleukodystrophy
- Substances:Elivaldogene Autotemcel
Countries:France
France- Participants:0–17 years
- Substances:Elivaldogene Autotemcel
Not recruiting
Chronic myeloid leukaemia
Not recruitingRegistered drugNo placebo
Study of ponatinib and azacitidine combination treatment in patients with accelerated phase or blast crisis chronic myelogenous leukemia
Registered drugNo placebo
- Disease:Chronic myeloid leukaemia
- Substances:AzacitidinePonatinib
Countries:France
France- Participants:18–64 years · 65+ years
- Substances:Azacitidine
Not recruiting
Haemophagocytic lymphohistiocytosis
Not recruitingInvestigationalNo placebo
Study on Itacitinib for Treating Non-Severe Hemophagocytic Lymphohistiocytosis in Adults
InvestigationalNo placebo
- Disease:Haemophagocytic lymphohistiocytosis
- Substances:Itacitinib
Countries:France
France- Participants:18–64 years · 65+ years
- Substances:Itacitinib
Not recruiting
Factor VIII deficiency
Not recruitingRegistered drugNo placebo
Study on Emicizumab for Patients with Mild or Moderate Hemophilia A Without FVIII Inhibitors
Registered drugNo placebo
- Disease:Factor VIII deficiency
- Substances:Emicizumab
Countries:France
France- Participants:0–17 years · 18–64 years · 65+ years
- Substances:Emicizumab
Not recruiting
Pulmonary arterial hypertension
Not recruitingRegistered drug
Study Comparing the Effectiveness and Safety of Macitentan 75 mg and 10 mg for Patients with Pulmonary Arterial Hypertension
Registered drug
- Disease:Pulmonary arterial hypertension
- Substances:Macitentan
Countries:France
France- Participants:18–64 years · 65+ years
- Substances:Macitentan
Not recruiting
Study Comparing Abatacept and Tocilizumab for Adults with Rheumatoid Arthritis Not Responding to Previous Treatments
Not recruitingRegistered drugNo placebo
Study Comparing Abatacept and Tocilizumab for Adults with Rheumatoid Arthritis Not Responding to Previous Treatments
Registered drugNo placebo
- Substances:AbataceptTocilizumab
Countries:France
France- Participants:18–64 years · 65+ years
- Substances:Abatacept
Not recruiting
Hereditary neuropathic amyloidosis
Not recruitingInvestigationalNo placebo
Study on NTLA-2001 for Patients with Hereditary Transthyretin Amyloidosis with Polyneuropathy
InvestigationalNo placebo
- Disease:Hereditary neuropathic amyloidosis
- Substances:ZiclumeranSingle Guide Rna Targeting The Human Ttr Gene
Countries:France
France- Participants:18–64 years · 65+ years
- Substances:Ziclumeran
Not recruiting
Pulmonary fibrosis
Not recruitingInvestigational
Study of Inhaled Pirfenidone for Patients with Progressive Pulmonary Fibrosis
Investigational
- Disease:Pulmonary fibrosis
- Substances:Pirfenidone
Countries:France
France- Participants:18–64 years · 65+ years
- Substances:Pirfenidone
Not recruiting
Pulmonary arterial hypertension
Not recruitingInvestigational
Study of Sotatercept for Patients with Severe Pulmonary Arterial Hypertension at High Risk of Mortality
Investigational
- Disease:Pulmonary arterial hypertension
- Substances:Sotatercept
Countries:France
France- Participants:18–64 years · 65+ years
- Substances:Sotatercept
Not recruiting
Dermatomyositis
Not recruitingRegistered drugNo placebo
Study on Baricitinib for Treating New-Onset Juvenile Dermatomyositis in Children
Registered drugNo placebo
- Disease:Dermatomyositis
- Substances:Baricitinib
Countries:France
France- Participants:0–17 years · 18–64 years
- Substances:Baricitinib